Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a …
Y Takaoka, T Suzuki, D Yoneoka… - Cochrane Database …, 2021 - cochranelibrary.com
Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP‐
1RA) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) were approved for treating
people with type 2 diabetes mellitus. Although metformin remains the first‐line
pharmacotherapy for people with type 2 diabetes mellitus, a body of evidence has recently
emerged indicating that DPP4i, GLP‐1RA and SGLT2i may exert positive effects on patients …
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP‐
1RA) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) were approved for treating
people with type 2 diabetes mellitus. Although metformin remains the first‐line
pharmacotherapy for people with type 2 diabetes mellitus, a body of evidence has recently
emerged indicating that DPP4i, GLP‐1RA and SGLT2i may exert positive effects on patients …
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors and COVID-19 outcomes
A Foresta, L Ojeda-Fernandez, G Macaluso… - Clinical Therapeutics, 2023 - Elsevier
Purpose: It has been reported that dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like
peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) have a role in modulation of inflammation associated with coronavirus disease
2019 (COVID-19). This study assessed the effect of these drug classes on COVID-19–
related outcomes. Methods: Using a COVID-19 linkable administrative database, we
selected patients aged≥ 40 years with at least 2 prescriptions of DPP-4i, GLP-1 RA, or …
peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) have a role in modulation of inflammation associated with coronavirus disease
2019 (COVID-19). This study assessed the effect of these drug classes on COVID-19–
related outcomes. Methods: Using a COVID-19 linkable administrative database, we
selected patients aged≥ 40 years with at least 2 prescriptions of DPP-4i, GLP-1 RA, or …
以上显示的是最相近的搜索结果。 查看全部搜索结果